Yes they could - which means ANP holds 100% of market potential for EMA and USA.
Not a bad thing either way.
But the micro and macro evidence suggests Sarepta (or Pfizer) may want to partner.
Particularly Sarepta have a LOT to lose if ANP go alone and replicate efficacy in P2B.
The timing of events / coincidences just can't be ignored - on both sides.
.
Yes they could - which means ANP holds 100% of market potential...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
-0.002(2.63%) |
Mkt cap ! $66.71M | |||
| Open | High | Low | Value | Volume |
| 7.8¢ | 7.8¢ | 7.4¢ | $65.57K | 885.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2437 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 58139 | 1 |
View Market Depth
| Last trade - 15.08pm 23/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
-0.002 ( 4.11 %) |
||||
| Open | High | Low | Volume | ||
| 7.8¢ | 7.8¢ | 7.6¢ | 16333 | ||
| Last updated 10.38am 23/04/2024 ? | |||||
| PER (ASX) Chart |